Switching to Heated Tobacco: Is It Really Better for You?
"A comprehensive study reveals significant reductions in toxicant exposure when smokers switch from traditional cigarettes to heated tobacco products."
Smoking remains a leading cause of numerous health disorders, including lung disease, cardiovascular issues, and cancer. The primary culprit behind these diseases is the exposure to harmful toxicants released during the combustion of tobacco in traditional cigarettes.
Recognizing the urgent need to mitigate these health risks, researchers and public health advocates have been exploring various strategies to reduce toxicant exposure among smokers. One promising avenue involves the development and use of modified risk tobacco products (MRTPs), which aim to minimize the harmful effects associated with tobacco consumption.
Among the innovative approaches in this field, heated tobacco products (HTPs) have emerged as a potential alternative to traditional cigarettes. These products heat tobacco to a lower temperature, avoiding combustion and subsequently reducing the levels of harmful chemicals released. A recent study published in "Nicotine & Tobacco Research" investigates the impact of switching from conventional cigarettes to HTPs on the levels of biomarkers of exposure (BoE) in healthy Japanese subjects. This article delves into the findings of this study, exploring the potential benefits and implications of HTPs as a means to reduce toxicant exposure.
Current Use and Evidence Gaps
The CDC says heated tobacco products heat processed tobacco leaf so users can inhale nicotine into their lungs, and names IQOS and Eclipse among brands permitted for sale in the United States. It says more research is needed to understand their short- and long-term health effects. A 2024 study surveyed adults who had used a heated tobacco product authorized by the FDA as a reduced-harm product; that product was removed from the market after about two years of sales. The study examined how its introduction and removal affected users’ past and current tobacco behaviors.
The Harm-Reduction Narrative
An Imperial Brands timeline presents heated tobacco, also called “heat-not-burn,” as part of the Next Generation Products discussion and frames its history through public health advocacy and information. The timeline describes increasing evidence as supporting a potential role for heated tobacco in harm reduction, but the supplied material does not identify specific milestones or dates. A Tobacco Harm Reduction 101 brief describes heated tobacco products as devices that heat tobacco rather than burn it. The brief argues that smoke from combustible cigarettes is responsible for most harms and claims that avoiding combustion means HTPs pose significantly less risk.
The Science Behind the Switch: How HTPs Reduce Toxicant Exposure
The study, a randomized controlled trial, focused on assessing whether switching from combustible cigarettes to HTPs could reduce biomarkers of toxicant exposure (BoE). Conducted on healthy Japanese smokers, the research compared the effects of using a novel HTP (glo™/THP1.0) and an in-market comparator (iQOS/THS) against continuing to smoke conventional cigarettes and quitting tobacco use altogether.
- Continuing to smoke conventional cigarettes.
- Switching to mentholated or non-mentholated variants of glo™.
- Switching to a non-mentholated variant of iQOS.
- Quitting nicotine and tobacco product use completely.
Reviews Examine Exposure and Harm
A systematic review and meta-analysis of biomarkers of exposure to carcinogens searched PubMed, Ovid, and Web of Science for randomized controlled trials published from January 2013 to March 2024. Another review, dated June 1, 2026, compared HTPs with combustible cigarettes across preclinical and interventional clinical studies, examining aerosol composition, toxicological exposure, and harm biomarkers. Its authors noted that toxicant-exposure reductions and associated health benefits remain uncertain. A separate review dated September 1, 2026 analyzed 24 studies published from 2016 to 2025 and described the evidence on harmful and potentially harmful compounds as fragmented and strongly influenced by industry-funded research.
Limits to the Reduced-Risk Case
A systematic review of interventional clinical trials says short-term, confined trials can provide evidence about toxicant exposure compared with cigarettes, but cannot establish whether HTPs reduce tobacco-related disease risks or benefit public health in real-world settings. A comprehensive systematic review reports that HTPs emit lower concentrations of some harmful substances also produced by conventional cigarettes, while releasing other toxicological and potentially carcinogenic compounds not emitted by conventional cigarettes. It also notes that prospective data linking HTP use to disease incidence and mortality are not available. A Tobacco-Free Kids evidence brief cautions that even if reduced-harm products prove less harmful, public-health benefits depend on people switching completely and not being offset by marketing that encourages youth and non-users to start.
Abstinence by Baseline Use Pattern
A prospective cohort study compared complete tobacco abstinence rates among people classified by their baseline tobacco use. Relative to exclusive combustible cigarette users, the rate ratio for complete abstinence was 0.85 among exclusive HTP users, with a 95% confidence interval of 0.71–1.02. Among dual users, the rate ratio was 0.49, with a 95% confidence interval of 0.42–0.58. These are the study’s reported comparisons and do not, on their own, establish why the groups differed.
The Future of Tobacco: HTPs as a Potential Harm Reduction Strategy
The study's findings suggest that HTPs have the potential to reduce exposure to smoke toxicants, offering a pathway to mitigate the harms associated with traditional cigarette smoking. As research in this area continues to evolve, HTPs may play a significant role in shaping the future of tobacco consumption and public health.
Biomarkers and Adverse Events
A systematic review assessed available data on heated tobacco products’ effects on biomarkers of potential harm and adverse events. Its stated comparisons include cigarettes, e-cigarettes, and smoking abstinence. The supplied abstract description does not report the review’s findings or quantify any effects. Its scope therefore signals areas being examined, rather than a conclusion that HTPs are safer or more harmful.
Market Direction and Uncertainty
A market report dated April 24, 2026 identifies consumer preference for reduced-harm nicotine products as a driver of the global heated tobacco market, attributing that interest to heightened awareness of alternatives to combustible cigarettes. A 2Firsts outlook says innovation is driving momentum and expects Asia to continue shaping the future of heated tobacco products, alongside competition over market leadership, new entrants, and prices. 6Wresearch says it tracks the global HTP market and publishes annual reporting on trends, growth drivers, revenue analysis, and forecasts. A United States market overview dated April 15, 2026 describes HTPs as alternatives combining real tobacco with new heating systems and notes regulatory controversies.